MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.yexcr.2025.114791

Медицинская библиотека · Experimental cell research · 2025

The BET degrader BETd-246 demonstrated significant anti-tumor efficacy in T-cell acute lymphoblastic leukemia by inhibiting TRAT1.

Ge Haixia, Bai Huike, Yu Juanjuan, Cheng Jia, Jin Zhongqin, Pan Jian, Li Xue, Shi Chunxia, Yang Yang, Hu Shaoyan, Tao Yanfang

СтатьяПеревод пока не подготовлен

Аннотация

T cell acute lymphoblastic leukemia (T-ALL) is a rare lymphoblastic leukemia characterized by T lymphocyte heterogeneity and diverse genetic abnormalities, accounting for approximately 15 % of childhood leukemias. BETd-246 serves as a tethering agent that links BETi-211 to thalidomide for the development of BET degraders. This compound has demonstrated superior efficacy in tumor treatment compared with traditional BET inhibitors. However, the anti-tumor effects and molecular mechanisms underlying the action of BETd-246 in T-ALL remain poorly understood. The aim of our study was to investigate the anti-tumor effects of BETd-246 and provide new insights into treatment strategies for T-ALL. In human T-ALL cell lines, BETd-246 induced degradation of BET proteins, particularly BRD4, at nanomolar concentrations. It effectively inhibited cell growth, disrupted the cell cycle, and promoted apoptosis in T-ALL cells in a concentration-dependent manner. The effects of BETd-246 were more pronounced than those of JQ1. In vivo experiments revealed that treatment with BETd-246 reduced proliferation and invasion of T-ALL cells and extended survival time in mouse models. RNA sequencing analysis indicated significant downregulation of T-cell receptor (TCR)-associated transmembrane adaptor 1 (TRAT1) expression in T-ALL cells treated with BETd-246. Knocking down TRAT1 resulted in increased growth inhibition and enhanced apoptosis within these cells. These findings suggest that TRAT1 plays a crucial role in mediating the effects of BETd-246 in T-ALL. Overall, our results indicate that BETd-246 is a promising therapeutic agent for treating this aggressive form of leukemia.

Для цитирования: Ge Haixia, Bai Huike, Yu Juanjuan, Cheng Jia, Jin Zhongqin, Pan Jian, Li Xue, Shi Chunxia, Yang Yang, Hu Shaoyan, Tao Yanfang. The BET degrader BETd-246 demonstrated significant anti-tumor efficacy in T-cell acute lymphoblastic leukemia by inhibiting TRAT1.. Experimental cell research. 2025. DOI: 10.1016/j.yexcr.2025.114791.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.